Keywords: atherogenics, ups, spend, inc, reported, revenues, months
AtheroGenics ups R&D spend 40%
Article | 25 February 2002
AtheroGenics Inc reported revenues for the three and 12 months toDecember 2001 of $1.1 million and $3.5 million, respectively, compared with $2.1 million and $8.2 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
